Testagen TG
Bioregulator peptide
Bioregulator tetrapeptide Lys-Glu-Asp-Gly, proposed as a male reproductive-tissue regulator; data cover DNA binding in vitro and bird models.
Evidence level. Little or no public data, or the exact identity is still being confirmed. About the badges
- Class
- Bioregulator peptide
- Category
- Bioregulator Peptides
- Type
- Single compound
- Abbreviation
- TG
- Development and regulatory status
- Not approved by FDA or EMA, research-only bioregulator peptide
What researchers study
Synthetic tetrapeptide Lys-Glu-Asp-Gly (KEDG) from the Khavinson programme, proposed as a regulator of male reproductive tissue. Published data found concern DNA binding in vitro and pituitary-related bird models, with no testis-specific study retrieved.
Research areas
- Nuclear uptake and DNA binding in vitro
- Thyroid and thymus recovery in hypophysectomised chickens
- Male reproductive-tissue regulation (proposed, little data)
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- cell culture
Labelled testagen entered the cytoplasm, nucleus and nucleolus of HeLa cells and showed sequence-dependent DNA binding in vitro, with preference for CAG-containing sequences
- bird
In pituitary-removed chickens, KEDG and AEDG reduced thyroid structural damage and raised thyroid hormone levels, with KEDG aiding thymus recovery more than AEDG
- evidence note
No testis-specific study or human trial was found, so the reproductive-tissue focus rests on the originators' proposal
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
